Drs kaniksha desai and julie ann sosa discuss the 2025 american thyroid association guidelines for the management of differentiated thyroid cancer. Based on the nccn guidelines, treatment selection for ovarian cancer is primarily determined by the histologic subtype, stage of disease, and whether the patient is a candidate for primary surgery. Men with localized prostate cancer are far more likely to die from something other than their cancer when treated according to current nccn guidelines. Dr maurie markman discusses an analysis focused on the impact of nccn recommendations on the use of multigene panel testing in pancreatic cancer. Updates to two genetic risk assessment guidelines now include prostate, endometrial, and gastric cancer to reflect the growing understanding of hereditary cancer risk and value of genetic testing. National comprehensive cancer network (nccn) 16th annual conference
Read clinically focused news coverage of key developments from the meeting. Fda reviewers flagged trial uncertainties for nearly 80% of cancer drugs approved from 2019 to 2022, but few were reported in journals or national comprehensive cancer network (nccn) guidelines.
WATCH
